Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients

HIV Medicine

Volumn 7, Issue 1, 2006, Pages 10-15

  Palacios Muñoz, Rosario ^a,c   Santos, J ^a   Garcia A ^b   Castells, E ^a   Gonzalez M ^a   Ruiz, J ^a   Marquez M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

^c NONE   (Spain)

Author keywords

Cardiovascular risk; HAART; Hypertension; Pulse pressure

Indexed keywords

ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNE STATUS; LIPID ANALYSIS; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE PRESSURE; RISK ASSESSMENT; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UNIVARIATE ANALYSIS; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; ANTHROPOMETRY; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED;

EID: 33644913349     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00333.x     Document Type: Article

References (31)

1. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSida Study Group. Lancet 1998; 352: 1725-1730.
3. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-1430.
4. Hicks C, Currier J, Sax P, Sherer R, Wanke C. Current management challenges in HIV: Tolerability of antiretrovirals and metabolic complications. AIDS Patient Care STDs 2003; 17: 221-233.
5. Currier JS. Cardiovascular risk associated with HIV therapy. J Acquir Immune Defic Syndr 2002; 31: S16-S32.
6. Rhew DC, Bernal M, Aguilar D, Iloeje U, Goetz MB. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: A systematic review. Clin Infect Dis 2003; 37: 959-972.
7. Sklar P, Masur H. HIV infection and cardiovascular disease - Is there really a link? N Engl J Med 2003; 349: 2065-2067.
8. Santos J, Palacios R, González M, Ruiz J, Márquez M. Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Nétar study). Int J STD AIDS 2005; 16: 677-680.
9. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving PI. AIDS 1998; 12: F51-F58.
10. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy. A 5-year cohort study. Arch Intern Med 2000; 160: 2050-2056.
11. Palacios R, Santos J, Ruiz J, González M, Márquez M. Factors associated with the development of diabetes in HIV-infected patients on antiretroviral therapy: A case-control study. AIDS 2003; 17: 933-935.
12. Mattana J, Siegal FP, Sankaran RT, Singhal PC. Absence of age-related increase in systolic blood pressure in ambulatory patients with HIV infection. Am J Med Sci 1999; 317: 232-237.
13. Cattelan AM, Trevenzoli M, Sasset L, Rinaldi L, Balasso V, Codrobbi P. Indinavir and systemic hypertension. AIDS 2001; 15: 805-807.
14. Sattler FR, Qian D, Louie S et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15: 2001-2010.
15. Hadigan C, Meigs J, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2003; 32: 130-138.
16. Galindo Puerto MJ. Arterial hypertension and HIV - a new problem? Nutr Metab Disord HIV Infect 2002; 1: 33-37.
17. Gazzaruso C, Bruno R, Garzaniti A et al. Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21: 1377-1382.
18. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: Results from a Norwegian Study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22: 731-736.
19. Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2003; 4: 411-416.
20. Seaberg EC, Muñoz A, Lu M et al. HIV infection, HAART, and blood pressure: Results from the Multi-center AIDS Cohort Study. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA: February, 2003 [Abstract 744].
21. Friis-Moller N, Weber R, Reiss P et al. (DAD Study Group). Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
22. Joint National Committee. The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
23. Kannel WB, Vasan RS, Levy D. Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values? Hypertension 2003; 42: 453-456.
24. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP). J Am Med Assoc 2001; 285: 2486-2497.
25. 2) and triceps skin-fold thickness. Am J Clin Nutr 1991; 53: 839-846.
26. Carr A. HIV protease inhibitor-induced lipodystrophy syndrome. AIDS Rev 1999; 1: 29-36.
27. Banegas JR, Rodríguez-Artalejo F, De la Cruz Troca JJ, Guallar-Castillón P, del Rey Calero J. Blood pressure in Spain. Distribution, awareness, control and benefits of a reduction in average pressure. Hypertension 1998; 32: 998-1002.
28. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and United States. J Am Med Assoc 2003; 289: 2363-2369.
29. Behrens G, Dejam A, Schmidt H et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63-F70.
30. Mulligan K, Grunfeld C, Tai WW et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35-43.
31. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. J Am Med Assoc 2002; 287: 2570-2581.